No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 11 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Traws Pharma, Inc. (TRAW) stock was $0.52 as of Oct 6, 2026, 4:00 PM EDT, down 2.99% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -76.0% · 3-year avg -68.8%/yr · 5-year avg -64.1%/yr
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19.
Biotechnology · Newtown, PA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.21
Revenue Est.
$2.71M
Last Quarter Results
EPS
$-0.16
vs Estimate
$-0.34
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TRAW | $7.92M | $0.52 | -2.99% | -75.96% | -64.14% | -64.35% | N/A |
| 2APRE | $7.87M | $0.64 | -5.94% | -54.79% | -63.30% | N/A | vs TRAW |
| 3GTBP | $8.04M | $6.37 | +3.41% | -61.33% | -73.13% | -68.76% | vs TRAW |
| 4MEDS | $8.05M | $3.07 | -8.36% | -90.01% | -45.88% | -25.43% | vs TRAW |
| 5CNSP | $7.75M | $5.30 | +0.03% | -40.68% | -91.63% | N/A | vs TRAW |
| 6HSCS | $8.14M | $3.77 | -13.53% | +17.75% | N/A | N/A | vs TRAW |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$1.00
+92.3% upside
Low
$1.00
Current
$0.52
High
$1.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Quarter ending Mar 2027 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Quarter ending Sep 2027 | $-0.50 | $-0.50 | $-0.50 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.23 | $-1.20 | $-1.17 | 1 |
| FY 2027 | $-1.87 | $-1.24 | $-0.59 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Sep 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| FY 2026 |
| $300000.00 |
| $300000.00 |
| $300000.00 |
| 2 |
| FY 2027 | $13.10M | $13.10M | $13.10M | 1 |
